Cargando…

Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueno, Shin-Ichi, Saiki, Shinji, Fujimaki, Motoki, Takeshige-Amano, Haruka, Hatano, Taku, Oyama, Genko, Ishikawa, Kei-Ichi, Yamaguchi, Akihiro, Nojiri, Shuko, Akamatsu, Wado, Hattori, Nobutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356654/ https://www.ncbi.nlm.nih.gov/pubmed/30597973 http://dx.doi.org/10.3390/cells8010014

Ejemplares similares

Shared Metabolic Profile of Caffeine in Parkinsonian Disorders
por: Takeshige‐Amano, Haruka, et al.
Publicado: (2020)

Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy
por: Mori, Akio, et al.
Publicado: (2019)

Nonmercaptalbumin as an oxidative stress marker in Parkinson’s and PARK2 disease
por: Ueno, Shin‐Ichi, et al.
Publicado: (2020)

Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease
por: Saiki, Shinji, et al.
Publicado: (2017)

Non-invasive diagnostic tool for Parkinson’s disease by sebum RNA profile with machine learning
por: Uehara, Yuya, et al.
Publicado: (2021)

A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
por: Nakamura, Ryota, et al.
Publicado: (2023)

Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease
por: Yamaguchi, Akihiro, et al.
Publicado: (2020)

A Retrospective Imaging Evaluation of Presynaptic Dopaminergic Degeneration in Multiple System Atrophy with Levodopa Induced Dyskinesia
por: Ueno, Shin-ichi, et al.
Publicado: (2020)

Metabolomics‐based identification of metabolic alterations in PARK2
por: Okuzumi, Ayami, et al.
Publicado: (2019)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
por: Fujimaki, Motoki, et al.
Publicado: (2018)

A metabolic profile of polyamines in parkinson disease: A promising biomarker
por: Saiki, Shinji, et al.
Publicado: (2019)

Reduced astrocytic reactivity in human brains and midbrain organoids with PRKN mutations
por: Kano, Masayoshi, et al.
Publicado: (2020)

Systemic Metabolic Alteration Dependent on the Thyroid‐Liver Axis in Early PD
por: Miyamoto, Kengo, et al.
Publicado: (2022)

Diffusion MRI Captures White Matter Microstructure Alterations in PRKN Disease
por: Koinuma, Takahiro, et al.
Publicado: (2021)

Current Status of Telemedicine for Parkinson’s Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey
por: Ogawa, Mayuko, et al.
Publicado: (2022)

White matter microstructures in Parkinson's disease with and without impulse control behaviors
por: Takeshige‐Amano, Haruka, et al.
Publicado: (2022)

White matter and nigral alterations in multiple system atrophy-parkinsonian type
por: Ogawa, Takashi, et al.
Publicado: (2021)

Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons
por: Yokota, Mutsumi, et al.
Publicado: (2021)

Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules
por: Ogawa, Takashi, et al.
Publicado: (2020)

Plasma taurine is an axonal excitability-translatable biomarker for amyotrophic lateral sclerosis
por: Nakazato, Tomoko, et al.
Publicado: (2022)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson’s disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group study (CONST-PD)
por: Hatano, Taku, et al.
Publicado: (2022)

A Cell-Based High-Throughput Screening Identified Two Compounds that Enhance PINK1-Parkin Signaling
por: Shiba-Fukushima, Kahori, et al.
Publicado: (2020)

Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson’s disease in Japan
por: Oyama, Genko, et al.
Publicado: (2023)

A Randomized Crossover Pilot Study of Telemedicine Delivered via iPads in Parkinson's Disease
por: Sekimoto, Satoko, et al.
Publicado: (2019)

Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromelanin MRI
por: Le Berre, Alice, et al.
Publicado: (2019)

Neurocognitive and psychiatric disorders‐related axonal degeneration in Parkinson's disease
por: Andica, Christina, et al.
Publicado: (2020)

Reduced ER-mitochondrial contact sites and mitochondrial Ca(2+) flux in PRKN-mutant patient tyrosine hydroxylase reporter iPSC lines
por: Yokota, Mutsumi, et al.
Publicado: (2023)

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
por: Okuzumi, Ayami, et al.
Publicado: (2023)

Multi-year whole-blood transcriptome data for the study of onset and progression of Parkinson’s Disease
por: Valentine, Matthew N. Z., et al.
Publicado: (2019)

Free-Water Imaging in White and Gray Matter in Parkinson’s Disease
por: Andica, Christina, et al.
Publicado: (2019)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2
por: Torii, Satoru, et al.
Publicado: (2023)

Istradefylline for Restless Legs Syndrome Associated with Parkinson’s Disease
por: Nuermaimaiti, Maierdanjiang, et al.
Publicado: (2018)

Metabolomic analysis data of MPP(+)-exposed SH-SY5Y cells using CE-TOFMS
por: Amo, Taku, et al.
Publicado: (2020)

Brain White-Matter Degeneration Due to Aging and Parkinson Disease as Revealed by Double Diffusion Encoding
por: Kamiya, Kouhei, et al.
Publicado: (2020)

Parkinson’s disease: deep learning with a parameter-weighted structural connectome matrix for diagnosis and neural circuit disorder investigation
por: Yasaka, Koichiro, et al.
Publicado: (2021)

p150(glued)-Associated Disorders Are Caused by Activation of Intrinsic Apoptotic Pathway
por: Ishikawa, Kei-Ichi, et al.
Publicado: (2014)

Identification of Licopyranocoumarin and Glycyrurol from Herbal Medicines as Neuroprotective Compounds for Parkinson's Disease
por: Fujimaki, Takahiro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q3q3b5mpr9eotdmiai34b5o1dk